Safety and Efficacy of Meplazumab in Patients With Coronary Artery Disease

NCT06572267 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Coronary Artery Disease

Interventions

DRUG: Mepolizumab low dose group
DRUG: Mepolizumab middle dose group
DRUG: Mepolizumab high dose group
DRUG: Saline

Sponsor

Xijing Hospital